|Bid||6.01 x 900|
|Ask||6.02 x 1400|
|Day's Range||5.71 - 6.13|
|52 Week Range||5.61 - 82.30|
|Beta (5Y Monthly)||1.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 08, 2023 - May 12, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.80|
In the latest trading session, Novavax (NVAX) closed at $5.76, marking a -0.35% move from the previous day.
The departing party is Greg Glenn, the president of research and development. First, research and development is a crucial area for biotechs like Novavax, as their future is heavily dependent on their pipeline programs. Second, Glenn was a longtime company mainstay, having joined Novavax in 2010.
Novavax (NASDAQ: NVAX) has had more than its share of ups and downs over the past few years -- and investors have been along for the ride. The stock soared 2,700% in 2020 as the company brought its coronavirus vaccine candidate through late-stage clinical trials. The biotech company's vaccine reached commercialization later than rivals.